Copyright © 2016
Aridis Pharmaceuticals, Inc.
5941 Optical Court, San Jose, CA 95138
Vu L. Truong, Ph.D.
Founder, Chief Executive Officer, and Director
Dr. Truong is a founder of Aridis and recently elected to the CEO position in 2014 after having served as the company's Chief Scientific Officer for the past 9 years. He has over 15 years experience in biopharmaceutical drug development, having held positions of increasing responsibilities in companies which were eventually acquired by larger entities, including Gene Medicine (sold to Megabios), Aviron (sold to Medimmune), and Medimmune (sold to Astra Zeneca). He has a life-
Chief Medical Officer
Dr. de Lame is an intensive care medical expert with strong experience in cardiovascular medicine and infectious diseases. He was a former executive at Merck and Warner Lambert (Pfizer) where he focused on clinical development at Merck and Warner-
Fred Kurland, J.D., M.B.A.
Chief Financial Officer
Mr. Kurland has more than 35 years experience in corporate finance, most recently as the CFO of Xoma. Mr. Kurland has a long and distinguished career as Chief Financial Officer of a number of biotechnology companies including Bayhill Therapeutics, Corcept Therapeutics, Genitope Corporation, Aviron, Protein Design Labs and Applied Immune Sciences, Inc. Previously, he held a number of financial management positions at Syntex Corporation between 1981 and 1995 including Vice President and Controller between 1991 and 1995. Mr. Kurland received his B.S. from Lehigh University and his J.D. and M.B.A. degrees from the University of Chicago.
Steven Chamow, Ph.D.
Dr. Chamow has more than 25 years of experience in biopharmaceutical product development and contributed to the development of three marketed products (Avastin, Natrecor, Vectibix). He served in leadership positions at a number of leading biotech companies, including Senior Vice President at Intradigm, Vice President of Process Sciences at Genitope Corporation and at Abgenix, Inc., (acquired by Amgen). He was also a senior scientist at Genentech. Dr. Chamow is author or co-
Elizabeth Leininger, Ph.D.
Regulatory and QA/QC
Dr. Leininger is an expert in regulatory affairs and quality, with more than 20 years of experience at CBER/FDA and at biopharmaceutical companies. She previously held senior management positions at Chiron (acquired by Novartis) and GSK. Additionally, she has significant expertise in global strategic development, licensing and post-
Jeffrey J. Fessler, J.D.
Acting General Counsel
Mr. Fessler has over 20 years of experience providing corporate and securities legal counsel in the biotechnology industry. He has extensive experience providing counsel in public offerings and private placements as well as mergers and acquisitions, joint ventures, proxy contests, restructurings and private equity and debt financings. He is a partner in the Sheppard Mullin law firm, and has practiced corporate and securities law at several large firms, including Akin, Gump, Strauss, Hauer & Feld and Orrick, Herrington & Sutcliffe, and Sichenzia Ross Friedman Ference LLP. Mr. Fessler holds a B.S. degree in Accounting from the University of Maryland and J.D. (magna cum laude) from New York Law School.
Breakthrough Therapies for
Antibiotic Resistant Infections